ReviewBritish journal of pharmacology2004
Proteinase-activated receptor pharmacology: trickier and trickier.
Review in British journal of pharmacology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 5 citations in OpenAlex.
- TRPV4 as a therapeutic target for joint diseases.Naunyn-Schmiedeberg's archives of pharmacology · 2015Review
- The emergence of proteinase-activated receptor-2 as a novel target for the treatment of inflammation-related CNS disorders.The Journal of physiology · 2007Review
Corrections and comments
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Proteinase-activated receptors (PARs) are G-protein-coupled receptors for serine and other proteinases. Peptide agonists of these receptors are frequently used to characterise the presence and role of PARs in cells and organ systems. However, the specificity of these peptides is questionable in some assay systems. In this issue, Hollenberg et al. report very different effects of PAR(4) receptors in various assays. Their results suggest the existence of unknown receptors and further highlight the need to use peptide PAR agonists with due caution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.